Merck hepatitis C drugs shine in easier to treat patients -study
April 10, 2014 at 01:00 AM EDT
April 10 (Reuters) - A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.